Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aptorum Group Ltd Cl A (APM)

Aptorum Group Ltd Cl A (APM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,077
  • Shares Outstanding, K 6,347
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,270 K
  • EBIT $ 0 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.32
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on 01/22/26
  • Next Earnings Date 04/29/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6500 +21.55%
on 02/13/26
0.8799 -10.21%
on 02/10/26
-0.0460 (-5.50%)
since 02/09/26
3-Month
0.6500 +21.55%
on 02/13/26
1.3800 -42.75%
on 12/12/25
-0.5299 (-40.14%)
since 12/09/25
52-Week
0.6500 +21.55%
on 02/13/26
4.4700 -82.32%
on 08/21/25
-0.1500 (-15.96%)
since 03/07/25

Most Recent Stories

More News
Aptorum Group Announces Merger with DiamiR Biosciences

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

APM : 0.7901 (-1.23%)
Aptorum Group Announces Strategic Merger with DiamiR Biosciences

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aptorum Group...

APM : 0.7901 (-1.23%)
Aptorum Group Releases Interim Financial Results for June 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aptorum Group...

APM : 0.7901 (-1.23%)
Aptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity Deficiency

Regulatory News:

APM : 0.7901 (-1.23%)
Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited

Regulatory News:

APM : 0.7901 (-1.23%)
Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Regulatory News:

APM : 0.7901 (-1.23%)
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Regulatory News:

APM : 0.7901 (-1.23%)
Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Regulatory News:

APM : 0.7901 (-1.23%)
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Regulatory News:

APM : 0.7901 (-1.23%)
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Regulatory News:

APM : 0.7901 (-1.23%)

Business Summary

Aptorum Group Limited is a pharmaceutical company. It engaged in developing and commercializing therapeutic and diagnostic technologies to tackle unmet medical needs. The company's therapeutic and diagnostic project primarily includes neurology, infectious diseases, gastroenterology, oncology and other...

See More

Key Turning Points

3rd Resistance Point 0.8622
2nd Resistance Point 0.8461
1st Resistance Point 0.8230
Last Price 0.7901
1st Support Level 0.7838
2nd Support Level 0.7677
3rd Support Level 0.7446

See More

52-Week High 4.4700
Fibonacci 61.8% 3.0108
Fibonacci 50% 2.5600
Fibonacci 38.2% 2.1092
Last Price 0.7901
52-Week Low 0.6500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar